ProMetic Announces the Appointment of its New Chief Medical Officer
February 06 2014 - 6:30AM
Marketwired
ProMetic Announces the Appointment of its New Chief Medical Officer
LAVAL, QUEBEC--(Marketwired - Feb 6, 2014) - ProMetic Life
Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today the appointment of Dr. John Moran as
its new Chief Medical Officer ("CMO"), effective as of March 1st,
2014.
Before joining ProMetic as its new CMO, Dr. Moran MD, FRACP,
FACP, FACPE, served as Vice President, Clinical Affairs - Home
Modalities at DaVita HealthCare Partners, Inc. where he was
responsible for the quality of care and related business issues for
over 20,000 home dialysis patients in over 900 care centers. Dr.
Moran is also a Consulting Professor in the Division of Nephrology
at Stanford University School of Medicine. Previously, Dr. Moran
served for 7 years as Senior Vice President, Clinical Affairs for
Satellite Healthcare, 4 years as Senior Vice President and Chief
Medical Officer for Vasca Inc. and more than 3 years as Vice
President for Clinical Development and Marketing for the Renal
Division of Baxter Healthcare Corporation.
"I am thrilled to be joining ProMetic as its new Chief Medical
Officer at such a critical time in its clinical development phase.
As a member of ProMetic's Board of Directors for the past 2 years,
I have closely followed the expansion of ProMetic's compounds into
a compelling therapeutic franchise. As a physician, it will be my
privilege to see ProMetic's small molecule drug candidates and
plasma derived therapeutics finally address many severe unmet
medical conditions and so significantly improve the quality of life
and outcomes for potentially thousands of patients" said Dr. Moran.
"As evidenced by the first-in-class efficacy demonstrated in some
of the most stringent preclinical fibrotic models and the recent
successful operational launch of the plasma purification facility,
ProMetic is now well positioned to become a leading provider of
innovative medical therapies", added Dr. Moran.
"Our recent progress and further anticipated advancement of our
lead drug candidates have made the creation of the Chief Medical
Officer position a corporate priority. We believe that Dr. Moran is
the perfect candidate to help us successfully bring forward our
compounds through the regulatory pathway given his deep knowledge
of both ProMetic and industry at large. His wealth of expertise in
senior executive positions related to clinical affairs, clinical
development and marketing in the field of nephrology and end-stage
renal diseases will play a key role in the development of our
valuable clinical assets", commented Mr. Pierre Laurin, President
and Chief Executive Officer of ProMetic.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized
expertise in bioseparation, plasma-derived therapeutics and
small-molecule drug development. ProMetic offers its state of the
art technologies for large-scale purification of biologics, drug
development, proteomics and the elimination of pathogens to a
growing base of industry leaders and uses its own affinity
technology that provides for highly efficient extraction and
purification of therapeutic proteins from human plasma in order to
develop best-in-class therapeutics and orphan drugs. ProMetic is
also active in developing its own novel small-molecule therapeutic
products targeting unmet medical needs in the field of fibrosis,
cancer and autoimmune diseases/inflammation. Headquartered in Laval
(Canada), ProMetic has R&D facilities in the UK, the U.S. and
Canada, manufacturing facilities in the UK and business development
activities in the U.S., Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about
ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, ProMetic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of ProMetic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations on page
26 of ProMetic's Annual Information Form for the year ended
December 31, 2012, under the heading "Risk and Uncertainties
related to ProMetic's business". As a result, we cannot guarantee
that any forward-looking statement will materialize. We assume no
obligation to update any forward-looking statement even if new
information becomes available, as a result of future events or for
any other reason, unless required by applicable securities laws and
regulations. All amounts are in Canadian dollars unless indicated
otherwise.
Pierre LaurinPresident and CEOProMetic Life Sciences
Inc.p.laurin@prometic.com+1.450.781.0115Frederic DumaisDirector,
Communications andInvestor RelationsProMetic Life Sciences
Inc.f.dumais@prometic.com+1.450.781.0115